Pharmaceuticals

NEPG

NEPG released FY2026 Q1 earnings on April 27 After-Market (BJT), actual revenue CNY 2.006 B, actual EPS CNY 0.019

NEPG to Release FY2026 Q1 Earnings on April 28 After-Market (BJT)

NEPG released FY2025 Annual Earnings on April 2 After-Market (BJT), Actual Revenue: CNY 7.075 B, Actual EPS: CNY 0.18

NEPG released FY2025 Q4 earnings on April 2 After-Market (BJT), actual revenue CNY 1.597 B, actual EPS CNY 0.0584

NEPG FY2025 Annual Earnings Release on April 3, 2026 After-Market (BJT)

NEPG released FY2025 Q3 earnings on October 27 After-Market (BJT), actual revenue CNY 1.625 B, actual EPS CNY 0.0307

NEPG released FY2025 9 Months Earnings on October 27 After-Market BJT, actual revenue CNY 5.478 B, actual EPS CNY 0.1212

NEPG FY2025 Q3 Earnings Release on October 28, After-Market (BJT)

NEPG released FY2025 Q2 earnings on August 26 Pre-Market (BJT), actual revenue CNY 1.905B, actual EPS CNY 0.0654

NEPG released FY2025 Semi-Annual earnings on August 26 Pre-Market (BJT), actual revenue CNY 3.853 B, actual EPS CNY 0.09

NEPG to Release FY2025 Semi-Annual Earnings on August 27, 2025 (BJT)

Northeast Pharmaceutical ESG Rating Results Announced

Northeast Pharmaceutical's Fosfomycin Trometamol API Passes EU High-end Registration

Northeast Pharmaceutical Group's Q1 2025 Net Profit Down 36.98%

NEPG released FY2025 Q1 earnings on April 28 During-Market BJT, actual revenue CNY 1.947 B, actual EPS CNY 0.025

NEPG FY2025 Q1 Earnings Release Scheduled for April 29 During-Market BJT

Northeast Pharmaceutical Subsidiary Obtains Drug Registration Certificate for Levetiracetam Extended-Release Tablets

NEPG released FY2024 annual earnings on April 2 After-Market BJT, actual revenue CNY 7.503 B, actual EPS CNY 0.29

NEPG released FY2024 Q4 earnings on April 2 After-Market (BJT), actual revenue CNY 1.369 B, actual EPS CNY 0.1478

NEPG to Release FY2024 Annual Earnings on April 3, 2025, After-Market BJT

000597

NEPG announced that its revenue for the third quarter was 1.625 billion yuan, a decrease of 17.28%; net profit was 43.5245 million yuan, a decrease of 14.92%. Revenue for the first three quarters was 5.478 billion yuan, a decrease of 10.69%; net profit was 173 million yuan, a decrease of 16.96%

Zhitong

NEPG: The net profit for the third quarter was 43.5245 million yuan, a decrease of 14.92%

NEPG announced that its holding subsidiary Beijing Dingcheng Peptide Source Biotechnology Co., Ltd. has received the "Drug Clinical Trial Approval Notice" issued by the National Medical Products Administration. The drug name is DCTY0801 injection, and the indication is for EGFRvIII positive recurrent or progressive high-grade glioma. The approval of this clinical trial is an important milestone in the research and development process of this product, which will accelerate the progress of the company's research products and enhance the company's core competitiveness in the field of cancer treatment

NEPG: The holding subsidiary has obtained approval for drug clinical trials

Recently, the board of directors of Northeast Pharmaceutical Group Co., Ltd. received a written resignation letter from Chief Financial Officer Zhou Yana, who has resigned due to personal health reasons. The resignation will take effect from the date it is delivered to the board and will not affect the normal operation of the company. The board will appoint a new Chief Financial Officer as soon as possible, and in the meantime, the duties will be performed by Director and General Manager Cai Yonggang. As of the announcement date, Zhou Yana holds 120,000 shares of the company, and the subsequent management of shares will be carried out in accordance with relevant regulations

NEPG: Chief Financial Officer Zhou Yana resigns due to health reasons

NEPG announced that in the first half of 2025, operating revenue was 3.853 billion yuan, a year-on-year decrease of 7.58%. Net profit was 129 million yuan, a year-on-year decrease of 17.62%. The company plans not to distribute cash dividends, not to issue bonus shares, and not to convert reserves into share capital

NEPG: Net profit of 129 million yuan in the first half of 2025, a year-on-year decrease of 17.62%

300147

China Galaxy Securities released a research report stating that cell gene therapy (CGT) has entered a period of realization of results, becoming the most promising development direction in the biopharmaceutical field. CGT has a high outsourcing ratio and high market concentration, with CXO expected to benefit first. Focus on companies with high pipeline maturity and good clinical trial data. Products such as CAR-T and TCR-T are being launched one after another, and the industry's prosperity continues to improve, with active investment and financing

CNI BIOMEDICINE

China Galaxy Securities: Cell gene therapy has entered the stage of result realization, and CXO is expected to benefit first

According to the Zhitong Finance APP, Northeast Pharmaceutical announced that the company recently received the Certificate of Suitability for European Pharmacopoeia (referred to as "CEP Certificate") issued by the European Medicines Agency. The relevant raw material name is Fosfomycin Trometamol. Fosfomycin Trometamol is an antibiotic used for respiratory infections, lower urinary tract infections such as cystitis, urethritis, and intestinal infections, as well as skin and soft tissue infections caused by sensitive pathogenic bacteria

NEPG: The active pharmaceutical ingredient fosfomycin trometamol has received CEP certification

Northeast Pharmaceutical's wholly-owned subsidiary, Dongyao Group Shenyang Shide Pharmaceutical Co., Ltd., has obtained the drug registration certificate for L-Carnitine Oral Solution issued by the National Medical Products Administration, with the approval number Guo Yao Zhun Zi H20253799, valid until March 31, 2030. This drug is used for the treatment of primary systemic carnitine deficiency and secondary carnitine deficiency caused by congenital metabolic disorders. The acquisition of this certificate will enrich the company's product line, enhance market competitiveness, and create new market opportunities

NEPG: Subsidiary obtains drug registration certificate for L-carnitine oral solution

NEPG announced that Fangda Steel will increase its holdings by 1.5175 million shares through the Shenzhen Stock Exchange from April 9 to April 15, 2025, accounting for 0.106% of the total share capital. After the increase, the controlling shareholder and its concerted parties will hold 786 million shares, accounting for 55.00% of the total share capital. The increase plan has not yet been completed, and Fangda Steel will continue to increase its holdings

NEPG: Fangda Steel has cumulatively increased its holdings in the company by 1.5175 million shares

NEPG's wholly-owned subsidiary has obtained the drug registration certificate for Levetiracetam Extended-Release Tablets, suitable for adjunctive treatment of partial seizures in patients aged 12 and above. This registration certificate will enrich the company's product line, enhance market competitiveness, and create new market opportunities

NEPG subsidiary obtains drug registration certificate for Levetiracetam extended-release tablets

NEPG released its 2024 annual report, with operating revenue of 7.503 billion yuan, a year-on-year decrease of 8.98%. The net profit attributable to shareholders was 410 million yuan, a year-on-year increase of 14.34%. The net profit after deducting non-recurring gains and losses was 312 million yuan, a year-on-year increase of 18.97%. The basic earnings per share were 0.29 yuan, and it is proposed to distribute a cash dividend of 1 yuan (including tax) for every 10 shares to all shareholders

NEPG(000597.SZ)